The Brazilian Journal of Infectious Diseases

ISSN: 1413-8670

The Brazilian Journal of Infectious Diseases is the official publication of the Brazilian Society of Infectious Diseases (SBI). It aims to publish relevant articles in the broadest sense on all aspects of microbiology, infectious diseases and immune response to infectious agents.
The BJID is a bimonthly publication and one of the most influential journals in its field in Brazil and Latin America with a high impact factor. Since its inception it has garnered a growing share of the publishing market.

Indexed in:

Scopus, Medline, Directory of Open Access Journals (DOAJ), PubMed Central (PMC), Science Citation Index Expanded (SCIE), SCImago Journal Rank (SJR), SNIP

RSS

Contact

Alert

Newsletter

Impact factor

The Impact Factor measures the average number of citations received in a particular year by papers published in the journal during the two preceding years.

© Clarivate Analytics, Journal Citation Reports 2025

Impact factor 2025

2.0

Citescore

CiteScore measures average citations received per document published.

Citescore 2025

3.2

SJR

SRJ is a prestige metric based on the idea that not all citations are the same. SJR uses a similar algorithm as the Google page rank; it provides a quantitative and qualitative measure of the journal's impact.

SJR 2025

0.549

SNIP

SNIP measures contextual citation impact by wighting citations based on the total number of citations in a subject field.

SNIP 2025

0.627

Time to first decision

The median number of days it takes for an article to go from submission to first editorial decision.

Time to first decision

42 days

View more metrics

Open Access Option

Journal Information

Back to article

Statistics

Follow this link to access the full text of the article

IN VITRO ACTIVITY OF AZTREONAM-AVIBACTAM AGAINST CLINICAL ISOLATES OF ENTEROBACTERALES COLLECTED IN BRAZIL FOR THE ATLAS SURVEILLANCE PROGRAM, 2018–2023

Lorena Cristina Correa Fehlberg

Corresponding author

lorena.fehlberg@pfizer.com

Corresponding author:

, Camilla Natal De Gaspari, Daniela V Pachito

Laboratórios Pfizer Brasil; São Paulo, SP, Brazil

Read

891

Times
was read the article

423

Total PDF

468

Total HTML